More hyperacute trials needed, get your doctor to request these be setup and run.
http://www.nature.com/jcbfm/journal/vaop/ncurrent/full/jcbfm2012166a.html
Glibenclamide is neuroprotective against cerebral ischemia in rats. We
studied whether glibenclamide enhances long-term brain repair and
improves behavioral recovery after stroke. Adult male Wistar rats were
subjected to transient middle cerebral artery occlusion (MCAO) for 90 minutes. A low dose of glibenclamide (total 0.6 μg) was administered intravenously 6, 12, and 24 hours
after reperfusion. We assessed behavioral outcome during a 30-day
follow-up and animals were perfused for histological evaluation. In
vitro specific binding of glibenclamide to microglia increased after
pro-inflammatory stimuli. In vivo glibenclamide was associated with
increased migration of doublecortin-positive cells in the striatum
toward the ischemic lesion 72 hours
after MCAO, and reactive microglia expressed sulfonylurea receptor 1
(SUR1) and Kir6.2 in the medial striatum. One month after MCAO,
glibenclamide was also associated with increased number of NeuN-positive
and 5-bromo-2-deoxyuridine-positive neurons in the cortex and
hippocampus, and enhanced angiogenesis in the hippocampus. Consequently,
glibenclamide-treated MCAO rats showed improved performance in the
limb-placing test on postoperative days 22 to 29, and in the cylinder
and water-maze test on postoperative day 29. Therefore, acute blockade
of SUR1 by glibenclamide enhanced long-term brain repair in MCAO rats,
which was associated with improved behavioral outcome.
No comments:
Post a Comment